NASDAQ:ANAB
Anaptysbio, Inc.
Anaptysbio, Inc.'s revenue grew 157.0% in fiscal 2025 to $234.6M while operating margin rose to 20.4%, its highest in 10 years. Free cash flow was $19.6M, 8.4% of revenue, and the diluted share count rose 1.3%.Summary generated from Anaptysbio, Inc.'s SEC filings. Latest annual report filed Apr 28, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$234.6M
Revenue growth+157.0%
Revenue, 5-yr CAGR+25.6%
Gross marginn/a
Operating margin20.4%
Net margin−5.6%
ROICn/a
Return on equity−24.5%
Debt / equityn/a
Free cash flow$19.6M
FCF margin8.4%
Share count change+1.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 63 | 10 | 17 | 91 | 235 |
| Operating income | −57 | −115 | −164 | −115 | 48 |
| Net income | −58 | −129 | −164 | −145 | −13 |
| Free cash flow | −47 | −74 | −122 | −136 | 20 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 8-KCurrent report
Sep 21, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KResults of a shareholder vote
Aug 11, 2026 - 8-KRegulation FD disclosure
Jul 30, 2026 - DEF 14AProxy statement
Jun 29, 2026 - 8-KEntry into a material agreement
Jun 22, 2026 - 8-KRegulation FD disclosure
May 29, 2026